Compare IRMD & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRMD | PCRX |
|---|---|---|
| Founded | 1992 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 910.4M | 1.0B |
| IPO Year | 2014 | 2011 |
| Metric | IRMD | PCRX |
|---|---|---|
| Price | $96.26 | $26.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $72.00 | $32.86 |
| AVG Volume (30 Days) | 74.4K | ★ 723.2K |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.71% | N/A |
| EPS Growth | ★ 13.00 | N/A |
| EPS | ★ 1.65 | 0.47 |
| Revenue | $80,511,268.00 | ★ $716,791,000.00 |
| Revenue This Year | $15.17 | $6.24 |
| Revenue Next Year | $10.15 | $9.53 |
| P/E Ratio | $58.33 | ★ $55.78 |
| Revenue Growth | ★ 12.91 | 3.14 |
| 52 Week Low | $47.48 | $18.17 |
| 52 Week High | $98.44 | $27.64 |
| Indicator | IRMD | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 75.36 | 72.55 |
| Support Level | $94.94 | $23.63 |
| Resistance Level | $98.44 | $24.81 |
| Average True Range (ATR) | 2.15 | 0.93 |
| MACD | 0.08 | 0.25 |
| Stochastic Oscillator | 80.50 | 100.00 |
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.